Rapport Therapeutics (NASDAQ:RAPP) Stock Falls 7.2% – Here’s What Happened

Posted by Stanley Muller on Sep 25th, 2026

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) dropped 7.2% during trading on Wednesday. The stock traded as low as $39.14 and last traded at $38.4660. 16,386 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 346,907 shares. The stock had previously closed at $41.47.

Wall Street Analyst Weigh In

RAPP has been the subject of a number of research analyst reports. Raymond James Financial reiterated a “strong-buy” rating on shares of Rapport Therapeutics in a report on Tuesday. UBS Group set a $80.00 target price on shares of Rapport Therapeutics in a research report on Wednesday. Leerink Partners assumed coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price target for the company. Wall Street Zen lowered Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $66.25.

Read Our Latest Stock Analysis on Rapport Therapeutics

Rapport Therapeutics Stock Down 0.9%

The stock’s 50 day moving average is $44.60 and its two-hundred day moving average is $38.85. The company has a market capitalization of $1.62 billion, a PE ratio of -11.13 and a beta of 1.02.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, sell-side analysts predict that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Insider Transactions at Rapport Therapeutics

In related news, CEO Abraham Ceesay sold 28,958 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total value of $1,390,273.58. Following the completion of the transaction, the chief executive officer owned 486,108 shares of the company’s stock, valued at $23,338,045.08. The trade was a 5.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 83,454 shares of company stock worth $3,945,181 over the last 90 days. Company insiders own 12.48% of the company’s stock.

Institutional Trading of Rapport Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RAPP. KBC Group NV purchased a new position in shares of Rapport Therapeutics in the 1st quarter valued at $30,000. State of Wyoming purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter worth $65,000. Meeder Asset Management Inc. bought a new stake in Rapport Therapeutics during the second quarter valued at about $116,000. AlphaCentric Advisors LLC boosted its position in Rapport Therapeutics by 6.8% during the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock valued at $201,000 after purchasing an additional 408 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in Rapport Therapeutics in the first quarter valued at about $215,000.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for disorders of the central nervous system. The company’s research centers on receptor-associated proteins, which help regulate neurotransmitter receptors and may provide opportunities to develop more selective therapies than those that target receptors broadly.

Rapport’s lead development program, RAP-219, is an orally administered investigational therapy designed to modulate AMPA receptors through their associated proteins.